CLAS Stock Overview
Claritas Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing therapies for patients with unmet medical needs.
+ 2 more risks
Claritas Pharmaceuticals, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CA$0.025|
|52 Week High||CA$0.28|
|52 Week Low||CA$0.025|
|1 Month Change||0%|
|3 Month Change||0%|
|1 Year Change||-90.39%|
|3 Year Change||-96.43%|
|5 Year Change||-98.96%|
|Change since IPO||-99.86%|
Recent News & Updates
|CLAS||CA Pharmaceuticals||CA Market|
Return vs Industry: CLAS underperformed the Canadian Pharmaceuticals industry which returned -64.4% over the past year.
Return vs Market: CLAS underperformed the Canadian Market which returned -4% over the past year.
|CLAS Average Weekly Movement||n/a|
|Pharmaceuticals Industry Average Movement||12.8%|
|Market Average Movement||10.1%|
|10% most volatile stocks in CA Market||18.3%|
|10% least volatile stocks in CA Market||3.8%|
Stable Share Price: Insufficient data to determine CLAS's volatility over the past 3 months.
Volatility Over Time: Insufficient data to determine CLAS's volatility change over the past year.
About the Company
Claritas Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing therapies for patients with unmet medical needs. The company was formerly known as Kalytera Therapeutics, Inc. and changed its name to Claritas Pharmaceuticals, Inc. in April 2021. The company was founded in 2014 and is headquartered in San Rafael, California.
Claritas Pharmaceuticals, Inc. Fundamentals Summary
|CLAS fundamental statistics|
Is CLAS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CLAS income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.048|
|Net Profit Margin||0.00%|
How did CLAS perform over the long term?See historical performance and comparison